Summary Eighteen patients with advanced breast cancer were commenced on treatment with high dose doxorubicin (100mg m2) or doxorubicin (100 mg m-2) and cyclophosphamide (500 mg m-2) at 2 weekly intervals. Three cycles of treatment were planned. rG-CSF was given subcutaneously for 10 days, starting 24 h after each cycle of chemotherapy. Sixteen out of 18 patients responded (89%) of whom six (33%) achieved a complete remission. Twelve (67%) completed the three planned cycles, four (22%) received two cycles and two (11%) received one cycle only. The median time to progression was 51 months and the median survival was 18j months. Neutropenia occurred after 89% of courses and 65% of courses were accompanied by a significant (WHO grade III or IV) infection. The duration of neutropenia was short (mean 5.4 Gundersen et al., 1990; Jonsson et al., 1991) . The response to conventional dose doxorubicin (60-70 mg m2 per 3 weeks) and to combination regimes containing doxorubicin are of the order of 50-60% (Carmo-Pereira et Steiner et al., 1983 and many others). At high doses () 100 mg m-2 per 3 weeks) response rates of over 80% have been reported in breast cancer patients (Jones et al., 1987 (Jones et al., , 1990 Bronchud et al., 1989) . Cyclophosphamide shows a similar, if less dramatic increase in effectiveness at increasing doses (Bramwell et al., 1983; Frei et al., 1989) .
Doxorubicin has been in clinical use for a period of over 15 years and has emerged as one of the most effective drugs in the treatment of metastatic breast cancer. The objective response rates to doxorubicin are largely dose related. Low dose regimes (<60 mg m2 per 3 weeks) achieve a low response rate (approximately 30%) and a particularly low rate of complete remission (Gundersen et al., 1986; Carmo-Pereira et al., 1987; Gundersen et al., 1990; Jonsson et al., 1991) . The response to conventional dose doxorubicin (60-70 mg m2 per 3 weeks) and to combination regimes containing doxorubicin are of the order of 50-60% (Carmo-Pereira et al., 1987; Steiner et al., 1983 and many others). At high doses () 100 mg m-2 per 3 weeks) response rates of over 80% have been reported in breast cancer patients (Jones et al., 1987 (Jones et al., , 1990 Bronchud et al., 1989) . Cyclophosphamide shows a similar, if less dramatic increase in effectiveness at increasing doses (Bramwell et al., 1983; Frei et al., 1989) .
The importance of drug scheduling and dose intensity on efficacy and toxicity of treatment have been increasingly appreciated. When the total dose of two regimes are equivalent, the dose intensity may be of critical importance as exemplified by the lower efficacy of 35 mg m-2 doxorubicin (q 3 weeks x 16) when compared to 70 mg m2 doxorubicin (q 3 weeks x 8) (Carmo-Pereira et al., 1987) . In a randomised study comparing the effect of scheduling on treatment outcome, there was no difference bet*een the equi-dose intensive regimes of doxorubicin 25 mg M2 (weekly x 12) versus 75 mg m-2 (3 weekly x 4 (Richards et al., 1992) . The relative importance of these two parameters is unknown when high dose doxorubicin is used. In a previous study by Bronchud et al. (1989) the response rate achieved with > 125 mg m-2 per 2 weeks (100%) appeared as good as, if not superior to a higher dose, but less dose intensive regime of 135 mg m-2 per 4 weeks (85%) (Jones et al., 19P7) . Both treatments were accompanied by substantial epithelial and haematological toxicity which on occasions, delayed subsequent treatments. The question then arises whether reducing the dose of doxorubicin further, whilst maintaining a dose intensive schedule would result in lesser toxicity without loss of treatment efficacy. To this end we have investigated the effects of doxorubicin given at 100 mg m2 at 2 weekly intervals in 18 patients with metastatic breast cancer. The first nine patients also received 500 mg m-2 cyclophosphamide and dose acceleration up to 2000 mg m-2 was intended. The epithelial toxicity of the combination chemotherapy appeared greater than expected and in consequence the remaining nine patients were treated with doxorubicin alone.
The major toxicity of this regime was expected to be myelosuppression, particularly neutropenia. Myelosuppressive effects of chemotherapy can be mitigated in part by use of recombinant haemopoietic growth factors which stimulate the proliferation and maturation of haemopoietic cells in the bone marrow (Bronchud et al., 1988; Groopman et al., 1989; Hermann et al., 1989) . One of these factors, rG-CSF, stimulates granulocyte proliferation in vivo (Souza et al., 1986; Cullor et al., 1990) and when given by continuous intravenous infusion, can reduce the duration of neutropenia in patients with chemotherapy induced myelosuppression (Bronchud et al., 1987; Recombinant human granulocyte stimulating factor (rG-CSF) was supplied by Chugai Pharmaceutical Company, Japan. It was produced in chinese hamster ovary cells after transformation with a vector derived from a human squamous carcinoma cell line (CHU-2) which produces G-CSF constitutively and is sequence identical to native human G-CSF. rG-CSF was supplied as a sterile lyophilised powder which was reconstituted with normal saline, and administered by subcutaneous injection for 10 days, starting 24 h after each cycle of chemotherapy. Following a preliminary dose ranging study with rG-CSF an initial dose of 5 mcg kg-' was selected. Successive dose escalation to 10 mcg kg-day-' and 1Omcg kg-' bd was permitted if there was grade IV neutropenia in the preceeding treatment cycle.
Response and toxicity were recorded in accordance with the UICC criteria (Hayward et al., 1977 
Results
The pre-treatment characteristics of patients are shown in delay were infection associated with neutropenia and mucositis (seven courses), oral mucositis with neutropenia (two courses), neutropenia alone (two courses), oral mucositis alone (one course) and general debility (one course). Two courses were delayed for convenience.
course was 11 days (range 0-22 days). Figure 3 shows the ANC profile of a typical patient and of two patients who had exceptional haematological toxicity. One patient (GE) failed to become neutropenic after each of three treatments. Another patient (AH) with bone marrow involvement had a low initital increment of ANC at 48 h (increased by 1.36 times) and a long time to recovery (14 days) after the first course.
Response
Anti-tumour effects Sixteen out of 18 patients responded (89%). Six patients achieved a complete response (33%) including two patients with liver metastases and one patient with bone marrow infiltration. Ten patients achieved a partial response (56%) including one patient who had a delayed response in the breast after 10 weeks. Stabilisation for a period of 3 months occurred in two patients (11%) with lung and liver metastases in addition to other sites of disease. No patient progressed on this treatment. Interestingly of the 16 patients who responded 11 responded rapidly after just one course of chemotherapy (three CR, eight PR). There were two additional responses after the second course (five CR, eight PR) and two further responses occurred after the third course of chemotherapy. One patient was not evaluated until the third course was completed.
The median time to progression was 166 days (5.5 months, range 1.5-8.5 months) and all patients had progressed by 18.4 months. Eleven patients (61%) were alive at 1 year and 8 patients (44%) survived 2 or more years. The median duration of survival was 18 months (range 2.5-26 months). The median time to progression of patients who received 1 or 2 courses (74 days) was significantly shorter than those completing three courses (224 days P <0.02) but there was no difference in survival between the two groups.
Toxicity
There were no treatment related deaths. Forty-eight hours after starting rG-CSF (day 4) the absolute neutrophil counts were increased by an average of 5.6 times (range 1.4-14.7) of the baseline values and counts of up to 75,000 x 106 neutrophils per litre were recorded. The frequency of haematological toxicity and infection are shown in Table II . Neutropenia (WHO grade III or IV) accompanied 89% of courses. Figure  2 shows the median absolute neutrophil count (ANC) of all patients during the first and third courses of treatment. The majority of patients (95%) had an ANC of less than 1,000 x 106 litre 8 days after treatment. The initial onset of the nadir was presumed to occur on day 5 or 6 as no patient was neutropenic on day 4. The mean duration of neutropenia was 5.4 days (0-13 days) and the average number of days to recovery (ANC > 1,000 x 106 litre) after the start of each After the third course the increment of ANC at 48 h was seven times baseline value and the time to recovery (11 days) had improved considerably and were comparable to those of patients without bone marrow infiltration.
Sixty-five per cent of courses (30/46) were accompanied by WHO grade III or IV infection (Table II) requiring inpatient treatment with broad spectrum antibiotics. Infection was confirmed by positive blood cultures in three cases and the following organisms were isolated: Pseudomonas aeroginosa, haemolytic Streptococcus, Staphylococcus aureus and group G Streptococcus. Prophylactic platelet transfusions were administered when the platelet counts were less than 20 x 109 litre and were required after 18 courses. All but two patients required blood transfusion for treatment related anaemia on one or two occasions. There was no significant difference in time to neutrophil recovery, neutrophil increments with rG-CSF, and red cell and platelet transfusion requirements between treatments courses 1, 2 and 3, indicating that myelosuppression was not cumulative.
The time to onset of nadir, duration of neutropenia and days to recovery, were not affected by altering the schedule of rG-CSF from once daily to twice daily, nor by increasing the dose from 5 mcg kg-' per day up to 20 mcg kg-' per day. Table III shows non-haematological toxic effects. Nausea and/or vomiting were experienced in 100% of courses but were mild to moderate in severity in all but four courses. Moderate to severe oral mucositis accompanied 43% of courses and 10% had associated genital ulceration. Palmar and plantar inflammation occurred after 43% of courses and was moderate to severe in two patients. One patient required surgical incision of a pseudo contracture of the palm formed by exfoliated keratin scale. There was no difference in severity or duration of mucocutaneous symptoms between patients receiving the doxorubicin/cyclosphosphamide combination and doxorubicin alone.
Minor transient abnormalities of liver function (WHO grade I rise in AST or ALK phos) were observed in four patients with previously normal values. All returned to normal in the post treatment period. The cardiac ejection fraction was significantly reduced in two patients. One patient was withdrawn from the trial after two courses (cumulative dose of doxorubicin 200 mgm2) and one had a reduced cardic ejection fraction after the third treatment cycle (cumulative dose of doxorubicin 300 mg m2). In both cases, the cardiac ejection fraction was within the normal range and there was no clinical evidence of cardiac failure. All patients were alopecic. There were no toxic effects directly attributable to the rG-CSF.
Discussion
We report an excellent initial therapeutic effect using an intensive regime of doxorubicin alone or with conventional dose cyclophosphamide in patients with locally advanced or disseminated breast cancer. The overall response rate of 89% (33% CR) compares favourably with that of previous studies using high dose doxorubicin (Bronchud et al., 1989; Jones et al., 1987) and with ablative therapy and autologous bone marrow transplantation (Jones et al., 1990; Tagima et al., 1989 Tagima et al., , 1988 . Particular advantages were the short duration of treatment (three treatments at approximately 2 weekly intervals) and rapid onset of therapeutic effect with most responses occurring after one or two treatments. Although rapidly achieved, responses were not durable. Some individ- The major non-haematological toxicity was mucositis affecting the oral cavity and perineum and palmar and plantar exfoliation. Oral mucositis severe enough to preclude eating solids was commonplace (43% of courses) and contributed significantly to overall discomfort between treatments. In addition, frequent disruption of mucosal barriers may have been a major factor contributing to infections during periods of neutropenia. These mucocutaneous effects were wholly attributed to doxorubicin as they were experienced equally by patients receiving doxorubicin alone and in combination with cyclophosphamide. Although it rarely warranted treatment delay per se, the epithelial toxicity was of sufficient severity to be dose limiting.
The importance of this study is three fold. It shows that rG-CSF given by a daily subcutaneous bolus for 10 days can substantially ameliorate the expected granulosuppressive toxicity of high dose doxorubicin. In this respect, it appears just as effective as continuous intravenous rG-CSF given over 14 days, (Bronchud et al., 1989) and has the advantage of greater convenience and avoiding some of the potential problems of central venous access. Secondly, this study defines the upper limit of bolus doxorubicin dose (100 mg m2/2 weeks) at which mucositis is limiting. Thirdly, it confirms that high dose doxorubicin is an effective, if toxic inducing agent. Whilst the degree of toxicity incurred may be acceptable in selected patients undergoing ablative therapy with/without bone marrow transplantation, it precludes wider application of high dose doxorubicin as first line therapy for metastatic breast cancer. Existing standard treatment regimes for the palliation of breast cancer remain unchallenged.
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